Login to Your Account



Other News To Note


Thursday, November 3, 2011

• Addex Pharmaceuticals Ltd., of Geneva, reported data showing that orally available candidate GLP1R PAM increased insulin secretion and decreased glycemia in response to glucose in preclinical models of diabetes. In the "db/db" model, in which insulin response to oral glucose in muted, GLP1R PAM (positive allosteric modulator) facilitated an insulin response and better control over blood glucose than vehicle or a marketed drug to treat Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription